Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Microbial contamination was reported in stagnant water in the duct of the manufacturing equipment.
| Brand name | MESALAMINE |
| Generic name | MESALAMINE |
| Active ingredient(s) | MESALAMINE |
| Distributed by / for | Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512 |
| NDC | 63304-175-13 |
| Full product label | Mesalamine Delayed-Release Tablets, USP 1.2 g per tablet, Rx Only, 120 Tablets per bottle, Once Daily, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited Survey No. 259/15, Dadra-396 191 (U.T. of D & NH), INDIA, NDC 63304-175-13. |
| Recalling firm | SUN PHARMACEUTICAL INDUSTRIES INC |
| Distribution | Nationwide in the USA |
| Quantity | 10,690 bottles |
| Recall initiated | 2024-01-18 |
| Report date | 2024-01-31 |
| Recall completed | — |
| Recall number | D-0268-2024 |
| Classification | Class II |
| FDA status | Completed |
| Origin on file | Princeton NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗